Sign up
Pharma Capital

Collagen Solutions CEO expects new business to boost full-year revenue, beating market forecasts

Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy tells Proactive Investors the firm expects full-year revenue to beat market forecasts, driven by deals to develop collagen products on behalf of third parties.

Rushdy also says the company is 'anxiously waiting' a CE Mark approval for its product ChondroMimetic, a minimally-invasive surgically placed scaffold that helps to repair knee cartilage.

 

View full COS profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.